BioPorto

BIOPOR · Nasdaq Copenhagen · Healthcare

1.08DKK +3.3%last day

Price as of 2 October 2026

The price over the past year, with dividends: −18.1%

Performance

1 month

−6.1%

1 year

−18.1%

3 years, per year

−13.8%

5 years, per year

−19.9%

Largest fall, 3 years

−80.4%

Below the peak now

−99.5%

Volatility, 1 year

52.4%

Return with dividends reinvested.

Key figures

P/E

60.9

P/B

6.4

Dividend yield

0.0%

Return on equity

+10.5%

Net margin

+23.3%

Market value

81 m USD

Quality, value and trend

Where BioPorto stands against every Nordic stock today. 100 is best.

Quality94

Profitability and a sound balance sheet over time. Better than 94% of Nordic stocks.

Value10

The price measured against earnings, assets and cash flow. Better than 10% of Nordic stocks.

Trend56

The price development over the past year. Better than 56% of Nordic stocks.

Combined52

Quality, value and trend together. Better than 52% of Nordic stocks.

About BioPorto

BioPorto is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 44 employees.

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabe…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis